NewsWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
More in Business
- ‘There are no rules now’: Zelensky reveals Putin’s alleged new war order Mint
- Mash-Up of Paramount and Warner Bros. Will Be Called Skydance The New York Times — Business
- G7 nations to release diesel stocks as wars in Europe and Middle East constrain fuel supplies CNBC — World News
- G7 to release up to 100m barrels of emergency oil and diesel reserves The Guardian — Business
- UK diesel price tops £2 a litre as G7 countries agree to release 100 million barrels of oil BBC News — Business